Outcomes of CD19-directed Chimeric Antigen Receptor T-cell Therapy for Transformed Non-follicular Lymphoma.

[1]  J. Abramson.  Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma. , 2022, Transplantation and cellular therapy.

[2]  P. Riedell,et al.  Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas. , 2022, Transplantation and cellular therapy.

[3]  J. Briones,et al.  Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma , 2022, Haematologica.

[4]  M. Kersten,et al.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[5]  B. Engels,et al.  Ibrutinib before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results from a Phase 1b Study , 2020 .

[6]  Matthew J. Frigault,et al.  Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. , 2020, Blood advances.

[7]  J. Byrd,et al.  Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. , 2020, Blood advances.

[8]  T. Kipps,et al.  Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[9]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[10]  J. Vose,et al.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Maloney,et al.  Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure. , 2020, Blood.

[12]  O. Tournilhac,et al.  State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 , 2019, Journal of Immunotherapy for Cancer.

[13]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[14]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[16]  J. Byrd,et al.  Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate , 2018, Blood.

[17]  I. Lossos,et al.  Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jeffrey A Jones,et al.  Ibrutinib treatment improves T cell number and function in CLL patients , 2017, The Journal of clinical investigation.

[19]  J. Friedberg,et al.  Transformation of marginal zone lymphoma (and association with other lymphomas). , 2017, Best practice & research. Clinical haematology.

[20]  C. June,et al.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms , 2017, Leukemia.

[21]  J. Byrd,et al.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. , 2016, Blood.

[22]  F. Cavalli,et al.  Histologic transformation in marginal zone lymphomas†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Jeffrey A Jones,et al.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.

[24]  A. Tsimberidou,et al.  Richter syndrome , 2005, Cancer.